Novel therapies and therapeutic approaches - Paris PSVD Meeting

Value of the Information & Strength of the Argument

The presentation offers valuable insights into the current state of therapeutic research in PSVD, drawing from the speaker’s direct experience with the API trial and recent scientific findings. The argumentation is well-structured, moving from trial experience to potential targets and approaches. The speaker supports his points with data from published studies (e.g., aspirin’s effect on venous thrombosis, bacterial translocation markers) and ongoing research, though some data are unpublished. He acknowledges uncertainties and the need for further research, which adds credibility. The discussion of drug repurposing and the importance of quality of life as an endpoint are particularly valuable for the field.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigor by referencing specific trials (API trial), published studies (e.g., aspirin and portal vein thrombosis, bacterial translocation in PSVD), and ongoing projects (REPO4EU). The speaker is transparent about limitations, such as the lack of preclinical models and the need for surrogate endpoints. The title accurately reflects the content. The sources cited are relevant and credible, though some are not formally cited with full references. The speaker also mentions the VALDIG criteria and the importance of standardized definitions, showing attention to methodological consistency.

The title accurately reflects the content, which focuses on novel therapies and therapeutic approaches for PSVD.

7/10

Presentation by a recognized expert in hepatology, based on ongoing clinical trials and published data. However, it is an opinion piece with limited peer-reviewed evidence presented, and some data are unpublished.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to the session on novel therapies for PSVD.
• 05:00Discussion of the API trial design and inclusion criteria.
• 10:00Challenges in patient recruitment and the importance of multicenter trials.
• 15:00Potential therapeutic targets: portal vein thrombosis, portal hypertension, and quality of life.
• 20:00Drug repurposing based on transcriptomic data: aspirin, statins, metformin.
• 25:00Evidence for immune system involvement and bacterial translocation in PSVD.
• 30:00Quality of life as an endpoint and patient-centered interventions.
• 35:00Conclusion: need for feasible clinical trials using stratification and surrogate endpoints.

• API trial (Apixaban for Portal Vein Thrombosis in PSVD) — Ongoing randomized controlled trial discussed by the speaker.
• Aspirin and venous thrombosis (2012 paper) — Referenced for aspirin's potential effect on portal vein thrombosis.
• Bacterial translocation in PSVD (Stefania Gioia's group) — Data on gut permeability and LPS in PSVD patients.
• REPO4EU project — European platform for drug repurposing mentioned as a future tool.

• VALDIG criteria for PSVD — Used for patient inclusion in the API trial and discussed for standardization.
• Carvedilol vs propranolol in cirrhosis — Referenced as a potential comparison for PSVD patients with clinically significant portal hypertension.